Physician profile
Maurice Jeter
NPI 1558543447
$833.84
in general payments reported to CMS, 2019-2025
13 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2021: $161 · 2022: $173 · 2023: $165 · 2024: $63.57 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $137.49 | 2021-2024 | Abilify Maintena, Abilify Asimtufii |
| Gilead Sciences, INC. | $111.62 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $98.56 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $85.10 | 2021-2024 | Uzedy |
| Janssen Pharmaceuticals, INC | $77.16 | 2019-2023 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $76.53 | 2019-2025 | Perseris, Sublocade |
| Alkermes, INC. | $62.50 | 2022 | |
| Lundbeck LLC | $49.48 | 2023 | Rexulti, Abilify Maintena |
| Bioxcel Therapeutics, INC. | $45.47 | 2023 | Igalmi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $31.89 | 2021-2023 | |
| Ironshore Pharmaceuticals INC. | $24.11 | 2022 | |
| Neurocrine Biosciences, INC. | $19.35 | 2023 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maurice Jeter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.